Jpmorgan Chase & CO Amicus Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 4,894,284 shares of FOLD stock, worth $34.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,894,284
Previous 7,214,250
32.16%
Holding current value
$34.2 Million
Previous $68 Million
41.23%
% of portfolio
0.0%
Previous 0.01%
Shares
20 transactions
Others Institutions Holding FOLD
# of Institutions
299Shares Held
332MCall Options Held
396KPut Options Held
249K-
Vanguard Group Inc Valley Forge, PA29.4MShares$205 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA29.1MShares$203 Million0.03% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$170 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY18MShares$126 Million1.88% of portfolio
-
William Blair Investment Management, LLC Chicago, IL14.6MShares$102 Million0.24% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $1.96B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...